As of March 7, 2024, Johnson & Johnson completed its acquisition of Ambrx. Visit the Johnson & Johnson website
Copyright © 2024 Ambrx. All Rights Reserved | Privacy | Site Map | Terms of Use
The Pioneer and Leader in Next Generation Antibody Drug Conjugates (ADCs)
Progress, News, and Updates
Read about our latest strides in precision biologics innovation. Stay in the know with our advancements through timely news, presentations, thought-provoking events, and insightful glimpses into the future.
Read here for a description of the expanded genetic code technology featured in Nature.
Latest News
Focused Oncology Portfolio
We are advancing enhanced antibody-drug conjugate, immuno-oncology conjugate and bispecific candidates as potential treatments for cancer.
Expanded Genetic Code Technology Platform
We incorporate synthetic amino acids into proteins within living cells. The result? Product candidates designed for highly stable, site-specific conjugation, overcoming the inherent limitations of conventional conjugation approaches.
ARX517 KOL Event at ESMO 2023
Featuring preliminary safety, efficacy, and PK data from APEX-01, a first-in-human study evaluating ARX517 in advanced prostate cancer patients presented at ESMO.